Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial.

Authors:

Abstract
6013 Background: Single agent VEGFR inhibitors and lenalidomide (L) have shown activity in advanced DTC, but combination therapy has not been evaluated. The goal of this study was to determine progression-free survival (PFS) in DTC patients (pts) treated with cediranib (C) or cediranib plus lenalidomide (C+L). Methods: Pts were required to have DTC with evidence of measurable and progressive disease within 12 months of enrollment. One prior VEGF inhibitor treatment was allowed and used as a stratification factor. Following a Phase 1 trial, pts were randomized in a 1:2 ratio to C 30mg daily or C 30mg daily plus L 15mg days 1-21 (C+L) every 4 weeks. An interim analysis was to be performed based on PFS after half (40) of the expected number of events (80) occurred. Results: 110 pts were enrolled and randomized from 2010 to 2015. Two pts withdrew consent before receiving therapy and were considered non-evaluable, leaving 108 for analysis (39 C and 69 C+L). Median follow-up time was 9.9 months. Baseline characteristics were similar in the two arms. Mean ages (range) were 62 (27-86) and 64 (24-83) in the C and C+L arms, respectively; 23% of pts in both arms received prior VEGF therapy. Grade 2 or higher AE’s at least possibly related to the study drugs in C vs C+L arms were: diarrhea (15% vs 10%), fatigue (26% vs 25%), generalized weakness (0% vs 5.8%), hypertension (23% vs 22%), oral mucositis (7.7% vs 4.3%), neutropenia (2.6% vs 14%), hand and foot syndrome (15% vs 4.3%), and proteinuria (0% vs 7.2%). At the planned interim analysis, the median PFS was 21 months in the C arm and 11 months in the C+L arm. The trial was then discontinued for futility with a conditional power of less than 15%. After an additional 10 months of follow-up, the PFS remained higher in the group randomized to C alone: 1 and 2-year PFS rates of 58% and 28% (median 14 months) in the C arm vs. 45% and 14% (median 11 months) in the C+L group (logrank p=0.39). Overall survival (OS) was similar: 1 and 2-year OS of 82% and 62% in C vs. 84% and 66% in C+L (logrank p=0.60). Conclusions: Single therapy with the VEGFR inhibitor cediranib showed promise in DTC, while the addition of lenalidomide was associated with lower PFS. Clinical trial information: NCT01208051.